-
JNJ-7706621
- names:
JNJ-7706621
- CAS号:
443797-96-4
MDL Number: - MF(分子式): C15H12F2N6O3S MW(分子量): 394.36
- EINECS: Reaxys Number:
- Pubchem ID: Brand:BIOFOUNT
| 货品编码 | 规格 | 纯度 | 价格 (¥) | 现价(¥) | 特价(¥) | 库存描述 | 数量 | 总计 (¥) |
|---|---|---|---|---|---|---|---|---|
| YZM001241-5mg | 5mg | 99.91% | ¥ 1890.00 | ¥ 1890.00 | 2-3天 | ¥ 0.00 | ||
| YZM001241-2mg | 2mg | 99.91% | ¥ 1040.00 | ¥ 1040.00 | 2-3天 | ¥ 0.00 |
| 中文别名 | |
| 英文别名 | |
| CAS号 | 443797-96-4 |
| Inchi | |
| InchiKey | |
| 分子式 Formula | C15H12F2N6O3S |
| 分子量 Molecular Weight | 394.36 |
| 溶解度Solubility | 生物体外In Vitro:DMSO溶解度≥ 125 mg/mL(316.97 mM)*"≥" means soluble可溶, but saturation unknown溶解度未知. |
| 性状 | |
| 储藏条件 Storage conditions | 粉末Powder: -20°C 3 years年 4°C 2 years年 / In solvent溶液中:-80°C 6 months月 -20°C 1 month月 |
JNJ-7706621(CAS:443797-96-4)实验注意事项:
1.实验前需戴好防护眼镜,穿戴防护服和口罩,佩戴手套,避免与皮肤接触。
2.实验过程中如遇到有毒或者刺激性物质及有害物质产生,必要时实验操作需要手套箱内完成以免对实验人员造成伤害
3.实验后产生的废弃物需分类存储,并交于专业生物废气物处理公司处理,以免造成环境污染Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.
1.实验前需戴好防护眼镜,穿戴防护服和口罩,佩戴手套,避免与皮肤接触。
2.实验过程中如遇到有毒或者刺激性物质及有害物质产生,必要时实验操作需要手套箱内完成以免对实验人员造成伤害
3.实验后产生的废弃物需分类存储,并交于专业生物废气物处理公司处理,以免造成环境污染Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.
| 产品说明 | JNJ-7706621 是一种有效的aurora kinase抑制剂,同时能有效抑制CDK1和CDK2,对 CDK1,CDK2,Aurora-A 和 Aurora-B 的IC50值分别为 9,3,11 和 15 nM |
| Introduction | JNJ706621 is a potentaurora kinaseinhibitor, and also inhibitsCDK1andCDK2, withIC50s of 9, 3, 11, and 15 nM for CDK1, CDK2, Aurora and Aurora, respectively. |
| Application1 | |
| Application2 | |
| Application3 |
JNJ-7706621 是一种有效的aurora kinase抑制剂,同时能有效抑制CDK1和CDK2,对 CDK1,CDK2,Aurora-A 和 Aurora-B 的IC50值分别为 9,3,11 和 15 nM。JNJ-7706621 is a potentaurora kinaseinhibitor, and also inhibitsCDK1andCDK2, withIC50s of 9, 3, 11, and 15 nM for CDK1, CDK2, Aurora-A and Aurora-B, respectively.
【1】.Huang S, et al. Synthesis and evaluation of N-acyl sulfonamides as potential prodrugs of cyclin-dependent kinase inhibitor JNJ-7706621. Bioorg Med Chem Lett. 2006 Jul 15;16(14):3639-41. Epub 2006 May 6.
【2】.Matsuhashi A, et al. Growth suppression and mitotic defect induced by JNJ-7706621, an inhibitor of cyclin-dependent kinases and aurora kinases. Curr Cancer Drug Targets. 2012 Jul;12(6):625-39.
【3】.Danhier F, et al. Active and passive tumor targeting of a novel poorly soluble cyclin dependent kinase inhibitor, JNJ-7706621. Int J Pharm. 2010 Jun 15;392(1-2):20-8.
【4】.Emanuel S, et al. The in vitro and in vivo effects of JNJ-7706621: a dual inhibitor of cyclin-dependent kinases and aurora kinases. Cancer Res. 2005 Oct 1;65(19):9038-46.
【2】.Matsuhashi A, et al. Growth suppression and mitotic defect induced by JNJ-7706621, an inhibitor of cyclin-dependent kinases and aurora kinases. Curr Cancer Drug Targets. 2012 Jul;12(6):625-39.
【3】.Danhier F, et al. Active and passive tumor targeting of a novel poorly soluble cyclin dependent kinase inhibitor, JNJ-7706621. Int J Pharm. 2010 Jun 15;392(1-2):20-8.
【4】.Emanuel S, et al. The in vitro and in vivo effects of JNJ-7706621: a dual inhibitor of cyclin-dependent kinases and aurora kinases. Cancer Res. 2005 Oct 1;65(19):9038-46.
对不起,暂无产品评价!
MSDS
SDS 1.0 中文
展开
SDS 1.0 英文
展开
- 相关产品
-
< >
- 推荐产品
-
< >
- 最新产品
-
< >
新闻
抱歉,暂无数据!


购物车 


